West Pharmaceutical ServicesWSTEarnings & Financial Report
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.
Revenue
$748.8M
Gross Profit
$273.6M
Operating Profit
$159.6M
Net Profit
$130.1M
Gross Margin
36.5%
Operating Margin
21.3%
Net Margin
17.4%
YoY Growth
2.3%
EPS
$1.78
West Pharmaceutical Services Q4 FY2024 Financial Summary
West Pharmaceutical Services reported revenue of $748.8M (up 2.3% YoY) for Q4 FY2024, with a net profit of $130.1M (down 5.0% YoY) (17.4% margin). Cost of goods sold was $475.2M, operating expenses totaled $114.0M.
Key Financial Metrics
| Total Revenue | $748.8M |
|---|---|
| Net Profit | $130.1M |
| Gross Margin | 36.5% |
| Operating Margin | 21.3% |
| Report Period | Q4 FY2024 |
West Pharmaceutical Services Annual Revenue by Year
West Pharmaceutical Services annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $3.1B |
| 2024 | $2.9B |
| 2023 | $2.9B |
| 2022 | $2.9B |
West Pharmaceutical Services Quarterly Revenue & Net Profit History
West Pharmaceutical Services results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $805.0M | +7.5% | $132.1M | 16.4% |
| Q3 FY2025 | $804.6M | +7.7% | $140.0M | 17.4% |
| Q2 FY2025 | $766.5M | +9.2% | $131.8M | 17.2% |
| Q1 FY2025 | $698.0M | +0.4% | $89.8M | 12.9% |
| Q4 FY2024 | $748.8M | +2.3% | $130.1M | 17.4% |
| Q3 FY2024 | $746.9M | -0.1% | $136.0M | 18.2% |
| Q2 FY2024 | $702.1M | -6.9% | $111.3M | 15.9% |
| Q1 FY2024 | $695.4M | -3.0% | $115.3M | 16.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $695.4M | $702.1M | $746.9M | $748.8M | $698.0M | $766.5M | $804.6M | $805.0M |
| YoY Growth | -3.0% | -6.9% | -0.1% | 2.3% | 0.4% | 9.2% | 7.7% | 7.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.60B | $3.49B | $3.68B | $3.64B | $3.62B | $3.95B | $4.11B | $4.27B |
| Liabilities | $921.7M | $912.6M | $923.0M | $961.1M | $935.1M | $1.02B | $1.05B | $1.09B |
| Equity | $2.68B | $2.58B | $2.75B | $2.68B | $2.68B | $2.93B | $3.05B | $3.18B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $118.2M | $165.0M | $180.1M | $190.1M | $129.4M | $177.1M | $197.2M | $251.1M |